Latent Adrenal Insufficiency: Concept, Clues to Detection, and Diagnosis. 2018

Toshihide Yamamoto

In 1855, Thomas Addison described an illness now known as Addison disease (AD) caused by damage to the adrenal cortex and manifesting in weakness, weight loss, hypotension, gastrointestinal disturbances, and brownish pigmentation of the skin and mucous membranes. Corticosteroid supplementation, corticotropin (adrenocorticotropic hormone [ACTH] of medicinal use) test, and anti-adrenal auto-antibodies (AA) have come into use in the 100 years since Addison's death. Following the methodological innovations, 4 disorders which share impaired response to corticotropin in common have been discovered (i.e., partial AD, apigmented adrenal insufficiency [AI], subclinical AI, and the AA-positive state exclusively in subjects proven to have an impaired response to corticotropin). As they are hidden, potentially serious conditions, these disorders are bound together as latent AI (LAI). Diagnosis of AD is often delayed, which may lead to adrenal crisis. If LAI were widely recognized, such delays would not exist and crises would be averted. The 3 existing guidelines do not refer much to LAI patients outside those in acute situations. To address this, information relevant to clinical manifestations and diagnostic tests of LAI was sought in the literature. Signs and symptoms that are useful clues to begin a diagnostic workup are presented for endocrinologists to identify patients with suspected LAI. The utility of 2 corticotropin test protocols is reviewed. To endorse LAI shown by the corticotropin test, monitoring items following corticosteroid supplementation are cited from the guidelines and supplemented with the author's observations. AA = anti-adrenal auto-antibodies; Ab = antibodies; ACA = AA detected by immunofluorescence; ACTH = adrenocorticotropic hormone; AD = Addison disease; AI = adrenal insufficiency; DHEA = dehydroepiandrosterone; GC = glucocorticoid; IFA = immunofluorescence assay; LAI = latent AI; LDT = low-dose test; MC = mineralocorticoid; 21OHAb = anti-21-hydroxylase Ab; ST = standard test; URI = upper respiratory infection.

UI MeSH Term Description Entries
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000224 Addison Disease An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES. Addison's Disease,Primary Adrenal Insufficiency,Primary Adrenocortical Insufficiency,Primary Hypoadrenalism,Addisons Disease,Adrenal Insufficiency, Primary,Adrenocortical Insufficiencies, Primary,Adrenocortical Insufficiency, Primary,Disease, Addison,Hypoadrenalism, Primary,Hypoadrenalisms, Primary,Insufficiencies, Primary Adrenocortical,Insufficiency, Primary Adrenocortical,Primary Adrenocortical Insufficiencies
D000309 Adrenal Insufficiency Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS. Adrenal Gland Hypofunction,Hypoadrenalism,Adrenal Insufficiencies,Hypofunction, Adrenal Gland
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D058070 Asymptomatic Diseases Diseases that do not exhibit symptoms. Asymptomatic Conditions,Asymptomatic States,Pre-Symptomatic Diseases,Presymptomatic Diseases,Asymptomatic Condition,Asymptomatic Disease,Asymptomatic State,Condition, Asymptomatic,Disease, Asymptomatic,Disease, Pre-Symptomatic,Disease, Presymptomatic,Pre-Symptomatic Disease,Presymptomatic Disease

Related Publications

Toshihide Yamamoto
January 2021, Frontiers in endocrinology,
Toshihide Yamamoto
October 1966, The Journal of the Medical Society of New Jersey,
Toshihide Yamamoto
March 1959, La Presse medicale,
Toshihide Yamamoto
February 1952, Vie medicale (Paris, France : 1920),
Toshihide Yamamoto
April 1974, Helvetica paediatrica acta,
Toshihide Yamamoto
January 2006, Current urology reports,
Toshihide Yamamoto
August 2003, Annals of internal medicine,
Toshihide Yamamoto
February 1989, BMJ (Clinical research ed.),
Toshihide Yamamoto
March 1989, BMJ (Clinical research ed.),
Toshihide Yamamoto
October 1952, Medecine et hygiene,
Copied contents to your clipboard!